Allogeneic peripheral blood stem cell transplantation (alloPBSCT) is an emerging technology. As this technology develops, transplant centers are concerned with looking for technologic advances that will result in improvements in clinical outcomes and lower costs. We provide comparative estimates of costs and resource use for alloPBSCT in comparison to allogeneic bone marrow transplantation (alloBMT) for persons with hematologic malignancies from the time of harvest to 100 days post transplant. A retrospective, cost-identification analysis was conducted for patients in two consecutive phase II clinical trials at the University of Nebraska Medical Center. Identical preparative regimens, graftversus-host disease prophylaxis, post-transplant hematopoietic colony-stimulating factor treatment regimens, and discharge criteria were used. Total median costs were $18 304 lower for alloPBSCT, with lower costs during recovery; specifically for hospitalization, platelet products, hematopoietic growth factors, intravenous hyperalimentation, supportive care agents, supplies, and antibacterial agents. This study provides preliminary evidence for short-term cost savings associated with alloPBSCT. However, concerns exist over the potential for higher costs due to preliminary reports of higher rates of chronic graft-versus-host disease, as well as more intensive induction regimens that may result in lower relapse rates. The premature adoption of new technologies based on short-term economic factors, in the absence of adequate clinical trial data, may prove to be ill-advised, particularly for complex medical treatments such as allogeneic transplantation. Keywords: hematopoietic stem cell transplantation; hematologic neoplasms; economics Both clinical and economic evidence of effectiveness are required prior to widespread adoption of new technologies. 2 The first allogeneic peripheral blood stem cell transplants (alloPBSCT) were performed in the early 1990s and as of April 1997 it is estimated that 2500 allogeneic peripheral blood stem cell transplantations have been performed worldwide.
of stem cell transplantation programs in North America and Europe. 2 The first allogeneic peripheral blood stem cell transplants (alloPBSCT) were performed in the early 1990s and as of April 1997 it is estimated that 2500 allogeneic peripheral blood stem cell transplantations have been performed worldwide. 3 With the exception of three large transplant centers for persons with hematologic malignancies, that have performed over 100 alloPBSCT procedures (MD Anderson, Fred Hutchinson and the University of Nebraska), most centers have performed less than 50 alloPBSCTs, and few have published their results. [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] In most of these studies, alloPBSCT has resulted in shorter durations of aplasia than alloBMT. Faster hematologic recovery has been attributed to the larger number of CD34 + cells transplanted and the higher proportion of partially committed progenitor cells in the transplants. 13 The evaluation of costs and outcomes for stem cell transplantation provides an important measure of 'value'. [14] [15] [16] [17] [18] [19] [20] [21] Welch 1 has pointed out that early assessments of value of stem cell transplantation pose unique methodologic problems. First, dissemination of new technologies is generally preceded by assessments of efficacy in the ideal setting, while effectiveness estimates in the usual practice setting occur later. Second, while short-term costs can be estimated in clinical trials, long-term costs are unknown. Despite these limitations, 'the assessment of value early in the development of new clinical strategies should be a prerequisite to their dissemination. ' 1 Dramatic improvements in hematopoietic recovery times, as noted in several phase II clinical trials, led to the rapid dissemination of autologous PBSCT over autologous BMT. An additional consideration was the expectation of lower costs for the autologous PBSCT procedure. Most large transplant centers operate under 'centers of excellence' contractual arrangements with large insurers and receive a fixed amount of money for each transplant, regardless of their actual costs. Similar clinical and economic considerations may apply to allogeneic stem cell transplantation. 2, 3 We have previously reported that, in comparison to alloBMT, alloPBSCT patients had more rapid hematopoietic engraftment. 22 In this study, we expand on these results by reporting on a comparative economic analysis of the two procedures. To our knowledge, this is the first report on the comparative costs and resource use of alloPBSCT and alloBMT.
Materials and methods

Patients
Adult patients with hematologic malignancies were treated on contemporaneous, sequential phase II clinical trials at the University of Nebraska Medical Center (UNMC) with high-dose therapy and stem cell rescue via HLA-matched alloPBSCT (n = 21) and alloBMT (n = 22) between 1994 and 1995. Identical preparative regimens, graft-versus-host disease prophylaxis, and post-transplant hematopoietic colony-stimulating factor treatment regimens were used. Clinical results from these trials have been reported previously. 22 Because we have previously observed that patterns of resource use and overall costs of care for stem cell transplant patients at the University of Nebraska Medical Center changed significantly over time, we excluded clinical and economic data from the nine earliest patients (treated in 1994) and concentrated our study on the patients transplanted in 1995 (alloPBSCT n = 21, alloBMT n = 13). 21 The cases described here represent about a quarter of the total alloPBSCT experience to date at the University of Nebraska.
Treatment protocol
The treatment protocol has been described previously. 22 Briefly, mobilized cells were collected from HLA-matched alloPBSCT donors (mobilization with granulocyte colonystimulating factor at 5 g/kg/day, subcutaneous injection, for 5 days). A minimum of 1 × 10 6 CD34 + cells/kg and 8 × 10 8 mononuclear cells/kg were collected during outpatient procedures from each donor. Leukopheresis was performed with a continuous blood flow separator, with a minimum of three leukopheresis procedures per transplant. Harvested cells were cryopreserved in 5% dimethylsulfoxide (DMSO) plus 6% hydroxyethylstarch. Bone marrow was harvested during day surgical procedures from the posterior iliac crests of donors using established methods. 23 The preparative regimen for both groups of patients consisted of etoposide (1800 mg/m 2 on day −7), cyclophosphamide (60 mg/kg/day on days −6 and −5), and total body irradiation (200 cGy twice daily, days −3, −2, −1 at a dose of 8-12 cGy/min).
Patients were housed continuously in single rooms with high-efficiency air filters in the transplantation unit. Patients received granulocyte colony-stimulating factor (G-CSF) 10 g/kg/day, via subcutaneous injection, daily, post transplant until neutrophil recovery (ANC 1500 cells/l for 3 consecutive days) beginning on day 0. GVHD prophylaxis consisted of intravenous cyclosporine (2 mg/kg every 12 h) beginning at day −3, followed by oral cyclosporine (6.25 mg/kg every 12 h) when tolerated and methotrexate, 5 mg/m 2 i.v., days +1, +3, +6 and +11. Broad-spectrum intravenous antibiotics were given for fevers Ͼ38°C or ANC Ͻ500 cells/l. No routine antifungal prophylaxis was given. Platelet transfusions consisting of random donor platelets, single donor platelets, and HLA cross-matched platelets (in a hierarchical treatment strategy, based on development of antibodies or clinical evidence of platelet refractoriness to transfusions) were administered for platelet counts Ͻ20 000 cells/l or if bleeding occurred. Packed red blood cells were transfused to maintain a hemoglobin level over 8 g/dl, if symptomatic. All patients were discharged via identical criteria: ANC у500 cells/l, absence of fever or infections, able to take oral medications, minimum oral intake of 1000 cm 3 fluid and 1000 kcal, controlled GVHD, absence of infection, ambulatory, and need for no more than one blood or platelet transfusion per day. After hospital discharge, patients received additional care and follow-up (including twice weekly complete blood counts, chemistries and physician visits; weekly chest radiographs; and bone marrow evaluations at day +28 and day +100) at the University of Nebraska Outpatient Cancer Clinic, unless re-hospitalization was necessary.
Cost analysis
The cost analyses were based on previously developed methods for economic evaluation of clinical studies. 19 In brief, detailed financial accounts for each patient were obtained, containing inpatient and outpatient information from the time of mobilization and harvest to 100 days post transplant. Resource utilization, on a per patient basis, as well as charge per resource were determined from these data. Department-specific ratios of costs to charges (RCCs) were utilized to calculate costs for each resource unit from inpatient charges (outpatient charges were multiplied by one RCC for the entire outpatient clinic). Per patient costs were calculated as the product of the resource utilization data and cost per resource unit. Overhead and administrative costs were included in the estimation of costs for each inpatient resource unit used. Results were reported as medians due to the right-skewed nature of this type of data (ie a small proportion of patients with drastically higher costs).
Differences in median values of clinical and economic results (number of days of hospitalization, number of days to reach ANC Ͼ500 cells/l and platelet count of 20 000/l, number of units of packed red blood cells and platelets transfused, total costs, harvest, induction, and recovery costs, and costs per service) were evaluated using the Wilcoxon rank-sum test. Sensitivity analyses determined costs associated with ranges of various parameters. Values were not discounted due to the short time interval of data collection.
Results
Clinical outcomes
Clinical characteristics and outcomes for each patient group, from this subset of the clinical trial data, are listed in Tables 1 and 2 . The median age of each group was about 40 years, two-thirds of the alloPBSCT and three-quarters of the alloBMT patients were male. A variety of hematologic malignancies were treated with these procedures. Three alloPBSCT patients had a one HLA mismatch, while all other patients had an HLA-identical transplantation. Good yields of CD34
+ stem cells and CFU-GM mononuclear cells were obtained in both treatment arms, with higher 557 counts for the alloPBSCT patients. In the clinical trial manuscript, the alloPBSCT patients had significantly shorter time period to ANC Ͼ500 cells/l (11.0 vs 16.5 for alloBMT), fewer days to platelets у20 000 cells/l (13 vs 24) and fewer number of days hospitalized (25 vs 31.5). 22 Clinical outcomes were similar between the two arms, the 100 day survival rate was 83% for alloPBSCT and 74% for alloBMT (P = 0.3585), the incidence of acute GVHD grade II-IV was 57% and 45% for alloPBSCT and alloBMT (P = 0.4654), respectively. In the subset of patients used for this economic study, these outcomes were the same, but the differences were no longer statistically significant due to the smaller sample size ( Table 2) .
Economic outcomes
Breakdowns of costs and resource profiles associated with each procedure are detailed in Tables 3A-C. Median harvest costs were significantly higher for alloPBSCT, $6688 vs $4262 for alloBMT (P Ͻ 0.05). Differences in costs were related to PBSC mobilization with granulocyte colony-stimulating factor, leukophereses, and costs for cell processing (Table 3A) . Induction costs were similar for alloPBSCT and alloBMT patients, with the largest costs being for room charges, chemotherapy, and TBI for both groups (Table 3B ). Significant differences in utilization and costs were incurred during the post-transplant recovery phase (Table 3C) . Post-transplant resources measured up to day 100 were used at a lower intensity for the alloPBSCT patients, including platelet transfusions (median of 8 units for alloPBSCT patients vs 14 units for alloBMT patients, P р 0.05), intravenous hyperalimentation (median of 14 days for alloPBSCT patients vs 21 days for the alloBMT patients, P р 0.05), and doses of pharmaceutical agents for supportive care, antibacterials, and hematopoietic colonystimulating factors. The total cost savings for the alloPBSCT patients were associated with significantly lower costs for platelet transfusions ($3024), hematopoietic growth factors ($1895), intravenous hyperalimentation ($1341), supportive care agents ($1628), supplies ($1151) and antibacterials ($876). The cost of hospitalization for alloPBSCT patients was also lower, by $4132, but this difference was not statistically significant. Median costs during the recovery phase were $51 283 for the alloPBSCT patients and $65 368 for the alloBMT patients, with a net saving of $14 085 for the alloPBSCT patients during this period. Overall, costs for harvest, induction and recovery to 100 days post transplant for the alloPBSCT patients were $18 304 less than alloBMT patients (P р 0.01). However, because the rate of chronic GVHD with alloPBSCT in comparison to alloBMT is not yet known, long-term comparisons of costs and resource use could not be derived.
Sensitivity analyses
Patients vary in their suitability for early hospital discharge and treatment with outpatient follow-up, antibiotics and blood products. The most important factors associated with cost-savings for the alloPBSCT patients were shortening of hospitalization and reduction of post-transplant G-CSF and supportive care agents. One-way sensitivity analyses were conducted to estimate how the results of the study withstand alternative assumptions in these areas. If the duration of hospitalization were identical for the two groups, the cost savings for alloPBSCT would be decreased by 36%. If pharmacy costs for hematopoietic colony-stimulating factors and supportive care agents for alloBMT patients were reduced to that of the alloPBSCT patients, the cost difference would be decreased by one-third.
Discussion
AlloPBSCT is a promising new procedure for the treatment of hematologic malignancies, but concerns exist about the comparative clinical and economic benefits compared to alloBMT. While we have previously reported 5.5 fewer days until neutrophil recovery, 11 fewer days until platelet recovery, and 5 days shorter hospitalizations for alloPBSCT patients, the earlier study did not include data on costs of care. 22 In this study a 19% short-term cost savings was noted for alloPBSCT patients from the time of stem cell harvest until 100 days following the stem cell transplantation. Our findings are similar to those from a preliminary report of 51 patients enrolled in a randomized phase III clinical trial in France, where the duration of severe neutropenia was shortened by 5 days, severe thrombocytopenia by 10 days, and costs were reduced by 20% with alloPBSCT. 24 Our study has implications for early assessments of the value of new allogeneic stem cell technologies. Economic data from the two single-site phase II trials can provide useful preliminary information related to the likely magnitude of short-term cost differences between alloPBSCT vs alloBMT, as well as insights into the types of data that will be required for subsequent evaluation during large multicenter phase III randomized studies. In this study, the economic analysis suggests that the magnitude of the economic savings is in the range of $18 000 to $19 000 for the 100 day period following the transplantation. Specific resource areas that differed between the two technologies were identified, with the largest portions of cost savings resulting from post-chemotherapy utilization; primarily hospitalization, platelet transfusions and hematopoietic colonystimulating factors.
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Table 3C
Median resource use and costs of stem cell transplantation recovery (to 100 days post transplant) The limitations of our study must be noted. First, the estimates of costs of care and resource utilization for alloPBSCT at the University of Nebraska Medical Center are likely to differ from those experienced at many other transplant centers. Clinical and economic results from a medical center with high levels of experience treating a large volume of patients with hematologic malignancies, stem cell transplantation and hematopoietic growth factors have been demonstrated to be lower than costs at centers with lower levels of experience. 16 Second, in our treatment protocol, at least three leukophereses were used to harvest donor peripheral blood stem cells. This type of protocol was followed due to the prospective clinical trial in which the donors were participating. Currently, in most cases, one to two apheresis procedures are often sufficient. 25 Third, the need for hematopoietic growth factor administration after allogeneic blood stem cell transplantation is still undergoing clinical investigation and has obvious cost implications. 26, 27 In the allogeneic stem cell transplant setting, the number of CD34 + cells infused is large, and the need for hematopoietic growth factor support is less apparent. The most important limitation was that the follow-up period was limited to 100 days after the stem cell transplantation procedure. Unlike transplantation in the autologous setting, chronic GVHD is an important late complication for allogeneic stem cell patients. In one of the largest cohorts reported to date, Storek et al 28 found that over half of 37
alloPBSCT patients who had received G-CSF mobilized peripheral blood stem cells from HLA-identical siblings developed clinical chronic GVHD as compared to only 32% among 37 historical controls of alloBMT patients who also had HLA-identical donors. 28 The differences in chronic GVHD rates were not apparent for at least 180 days of follow-up. The lack of economic information after the first 100 days in our study raises the concern that costs associated with chronic GVHD among the long-term survivors may more than offset early cost savings.
AlloPBSCT, while performed in only 2500 patients in Europe and North America, is an example of a new technology that is disseminating rapidly. In 1997, 22% of the allogeneic transplants reported to the European Blood and Marrow Transplant Registry and the North American Blood and Marrow Transplant Registry were of peripheral blood stem cells. 3 AlloPBSCT accounted for 26 cases reported to these Registries in 1994, 244 cases in 1995, and 515 cases in 1996.
Transplant programs in the United States and England compete for referrals on the basis of clinical outcomes and cost comparisons. For autologous stem cell transplantation, evidence of clinical benefits and cost savings in phase II trials resulted in rapid acceptance of autoPBSCT over autoBMT, necessitating early closure of an important phase III randomized trial in the United States which included clinical and economic comparisons of the two procedures.
If the usual scientific process of evaluating new technologies by phase II and subsequent phase III trials is not followed, knowledge of the long-term results of the two types of allogeneic stem cell transplantation could be jeopardized. If the switch to PBSCT occurs based on short-term economic results, more chronic GVHD and higher longterm costs could result. Also, more toxic conditioning regimens, that might improve the cure rate, would be penalized due to longer initial hospitalizations and higher shortterm costs.
